Erasca, Inc. (ERAS): R&D Expense
$92.85M
Year ended 2025-12-31
$108.88M
Trailing 12 months to 2026-06-30
-6.2%
3-year compound annual growth
+25.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $92.85M | -19.5% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $115.36M | +11.1% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $103.82M | -7.7% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $112.46M | +52.1% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $73.92M | +150.2% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $29.55M | n/a | 2022-03-24, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 2025-12-31 | $92.85M | -19.5% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $95.14M | -14.6% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $132.16M | -8.2% |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $4.4K | n/a |
| Harrow, Inc. (HROW) | 2025-12-31 | $20.94M | +71.2% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $90.43M | -6.5% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $79.16M | +37.9% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $109.82M | -3.7% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $168.06M | +20.8% |
Compare ERAS, IRWD, TNGX, OTLC side by side · Screen every company in Pharmaceutical Preparations ↗